Bruker (BRKR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
The 2026 Annual Meeting will be held virtually on May 21, 2026, with voting available online, by phone, or by mail.
Proxy materials are distributed electronically to reduce costs, with printed copies available upon request.
The meeting agenda includes director elections, an advisory vote on executive compensation, and ratification of the external auditor.
Forward-looking statements caution about risks from supply chain, macroeconomic, regulatory, and competitive factors.
Voting matters and shareholder proposals
Shareholders will vote to elect three Class II directors for terms expiring in 2029.
An advisory vote will be held on 2025 executive compensation (say-on-pay).
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 is on the agenda.
Shareholders may submit proposals for the 2027 meeting by December 11, 2026.
Board of directors and corporate governance
The board consists of 12 members divided into three classes, with a combined Chairman/CEO and a lead independent director.
All directors except the CEO are independent per Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating & Governance, each with defined charters and responsibilities.
Board and committees met regularly in 2025, with high attendance rates.
Director nominations consider experience, integrity, independence, and diversity of skills.
Latest events from Bruker
- Q2 2026 saw revenue and margin growth, offset by a $134.9M goodwill impairment charge.BRKR
Q2 2026 - Order momentum, global growth, and cost savings set the stage for margin expansion through 2027.BRKR
Jefferies Global Healthcare Conference 2026 - Directors elected, executive pay approved, and auditors ratified for 2026.BRKR
AGM 2026 - Q1 2026 revenue up 2.7%, EPS down, but FY guidance reaffirmed with strong bookings and cost savings.BRKR
Q1 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.BRKR
Proxy filing - FY25 revenue up 2.1% but margins fell; FY26 guidance targets EPS and margin expansion.BRKR
Q4 2025 - Q2 2024 revenue up 17.4% as acquisitions drive growth, but margins pressured by costs.BRKR
Q2 2024 - Innovation and acquisitions fuel growth in proteomics, diagnostics, and spatial biology.BRKR
Goldman Sachs 45th Annual Global Healthcare Conference - All proposals, including director elections and incentive plan, were approved by stockholders.BRKR
AGM 2025